Modern-Day Cardio-Oncology: A Report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’
Authors:
Open Access
- 1 December 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 5 (6) , 1083-1091
Abstract
During the ‘Heart Failure and World Congress on Acute Heart Failure 2018’, many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the ‘Heart Failure and World Congress on Acute Heart Failure 2018’. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.Keywords
This publication has 99 references indexed in Scilit:
- Patients With Heart Failure Have an Increased Risk of Incident CancerJACC, 2013
- Prevention of liver cancer cachexia-induced cardiac wasting and heart failureEuropean Heart Journal, 2013
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialThe Lancet Oncology, 2013
- Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant HemopathiesJACC, 2013
- Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort studyBreast Cancer Research, 2011
- Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2010
- Anthracycline-Induced CardiomyopathyJACC, 2010
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Journal of Clinical Oncology, 2009
- Anemia in Chronic Heart FailureCirculation, 2006
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004